Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
July 7, 2025
In the News
Louis Lehot Assesses Deal Trends in Shifting Market
Foley & Lardner LLP partner Louis Lehot assessed dealmaking trends in the Law360 article, "PE Dealmakers Best-Suited To Cut Through M&A Challenges."
July 3, 2025
In the News
Louis Lehot Highlights Opportunities and Challenges for M&A Market
Foley & Lardner LLP partner Louis Lehot highlighted opportunities and challenges for the M&A market in the Law360 article, "Mid-Year M&A Deal Flow Suffers Amid Global Instability."
July 2, 2025
In the News
John Strom and Peter Tomasi Quoted on Shift in Environmental Policy
Foley & Lardner LLP attorneys John Strom and Peter Tomasi commented on changes to federal environmental rules in the Utility Dive article, "Federal agencies, including FERC and DOE, revoke environmental review rules."